Knight Cardiovascular Institute, Oregon Health and Science University, Portland, Oregon, USA; Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Cardiovascular Research Imaging Center, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA; School of Business Studies, Stralsund University of Applied Sciences, Stralsund, Germany.
JACC Cardiovasc Imaging. 2022 Aug;15(8):1427-1438. doi: 10.1016/j.jcmg.2022.03.016. Epub 2022 May 11.
Increased inflammation and myocardial injury can be observed in the absence of myocardial infarction or obstructive coronary artery disease (CAD).
The authors determined whether biomarkers of inflammation and myocardial injury-interleukin (IL)-6 and high-sensitivity cardiac troponin (hs-cTn)-were associated with the presence and extent of CAD and were independent predictors of major adverse cardiovascular events (MACEs) in stable chest pain.
Using participants from the PROMISE trial, the authors measured hs-cTn I and IL-6 concentrations and analyzed computed tomography angiography (CTA) images in the core laboratory for CAD characteristics: significant stenosis (≥70%), high-risk plaque (HRP), Coronary Artery Disease Reporting and Data System (CAD-RADS) categories, segment involvement score (SIS), and coronary artery calcium (CAC) score. The primary endpoint was a composite MACE (death, myocardial infarction, or unstable angina).
The authors included 1,796 participants (age 60.2 ± 8.0 years; 47.5% men, median follow-up 25 months). In multivariable linear regression adjusted for atherosclerotic cardiovascular disease (ASCVD) risk, hs-cTn was associated with HRP, stenosis, CAD-RADS, and SIS. IL-6 was only associated with stenosis and CAD-RADS. hs-cTn above median (1.5 ng/L) was associated with MACEs in univariable analysis (HR: 2.1 [95% CI: 1.3-3.6]; P = 0.006), but not in multivariable analysis adjusted for ASCVD and CAD. IL-6 above median (1.8 ng/L) was associated with MACEs in multivariable analysis adjusted for ASCVD and HRP (HR: 1.9 [95% CI: 1.1-3.3]; P = 0.03), CAC (HR: 1.9 [95% CI: 1.0-3.4]; P = 0.04), and SIS (HR: 1.8 [95% CI: 1.0-3.2]; P = 0.04), but not for stenosis or CAD-RADS. In participants with nonobstructive CAD (stenosis 1%-69%), the presence of both hs-cTn and IL-6 above median was strongly associated with MACEs (HR: 2.5-2.7 after adjustment for CAD characteristics).
Concentrations of hs-cTn and IL-6 were associated with CAD characteristics and MACEs, indicating that myocardial injury and inflammation may each contribute to pathways in CAD pathophysiology. This association was most pronounced among participants with nonobstructive CAD representing an opportunity to tailor treatment in this at-risk group. (PROspective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).
在没有心肌梗死或阻塞性冠状动脉疾病(CAD)的情况下,也可以观察到炎症和心肌损伤的增加。
作者确定炎症和心肌损伤标志物——白细胞介素(IL)-6 和高敏心肌肌钙蛋白(hs-cTn)——是否与 CAD 的存在和程度相关,以及是否是稳定型胸痛患者发生主要不良心血管事件(MACE)的独立预测因素。
作者使用 PROMISE 试验的参与者,测量 hs-cTn I 和 IL-6 浓度,并在核心实验室分析计算机断层扫描血管造影(CTA)图像,以分析 CAD 特征:显著狭窄(≥70%)、高危斑块(HRP)、冠状动脉疾病报告和数据系统(CAD-RADS)分类、节段受累评分(SIS)和冠状动脉钙(CAC)评分。主要终点是复合 MACE(死亡、心肌梗死或不稳定型心绞痛)。
作者纳入了 1796 名参与者(年龄 60.2±8.0 岁;47.5%为男性,中位随访时间 25 个月)。在多变量线性回归中,校正了动脉粥样硬化性心血管疾病(ASCVD)风险后,hs-cTn 与 HRP、狭窄、CAD-RADS 和 SIS 相关。IL-6 仅与狭窄和 CAD-RADS 相关。hs-cTn 中位数以上(1.5ng/L)在单变量分析中与 MACE 相关(HR:2.1[95%CI:1.3-3.6];P=0.006),但在多变量分析中校正 ASCVD 和 CAD 后则不相关。IL-6 中位数以上(1.8ng/L)在多变量分析中与 ASCVD 和 HRP 校正后的 MACE 相关(HR:1.9[95%CI:1.1-3.3];P=0.03)、CAC(HR:1.9[95%CI:1.0-3.4];P=0.04)和 SIS(HR:1.8[95%CI:1.0-3.2];P=0.04),但与狭窄或 CAD-RADS 无关。在非阻塞性 CAD(狭窄 1%-69%)患者中,hs-cTn 和 IL-6 中位数以上的存在与 MACE 强烈相关(校正 CAD 特征后,HR:2.5-2.7)。
hs-cTn 和 IL-6 的浓度与 CAD 特征和 MACE 相关,表明心肌损伤和炎症可能各自促进 CAD 病理生理学的途径。这种相关性在非阻塞性 CAD 患者中最为明显,这为该高危人群的治疗提供了机会。(前瞻性多中心成像研究评价胸痛[PROMISE];NCT01174550)。